Put together, while the findings from this study strongly suggest orientin as a lead compound against PTP1B for the management of T2DM, further studies are imperative to focus on structural modifications of orientin to address the Lipinski's violations with a view to improve its druggable attributes as a novel PTP1B inhibitor. The gene discussed is PTPN1; the disease is type 2 diabetes mellitus.